Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD‐1 SU)

Marre, Michel; Shaw, J.; Brändle, Michael; Mohamed Wan Bebakar, Wan; Azmi Kamaruddin, Nor; Strand, Jorma; Zdravković, Marija; D. L. Thi, Tu; Colagiuri, Stephen; behalf of the LEAD‐1 SU study group, on

doi:10.1111/j.1464-5491.2009.02666.x

Public

Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD‐1 SU)

Published in Diabetic Medicine • Jan 14, 2009

Authors:

Michel Marre

J. Shaw

Michael Brändle

Abstract

AIM: To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n >or= 228) or placebo (n = 114) with glimepiride (2-4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes. METHODS: In total, 1041 adults (mean +/- sd), age 56 +/- 10 yea...

Subject

Liraglutide

Medicine

Glimepiride

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!